+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating new treatment options for metastatic cervical cancer, a condition where cancer has spread from the cervix to other parts of the body. This study focuses on the safety and effectiveness of combining sacituzumab tirumotecan sac-TMT, pembrolizumab, and bevacizumab, compared to standard treatments. The research aims to understand how well these medicines work together and whether they help people live longer or delay cancer progression. The study has two parts. In Part 1, eligible participants receive sac-TMT with pembrolizumab and bevacizumab to assess safety. In Part 2, all participants first undergo standard induction treatment with pembrolizumab, paclitaxel, and cisplatin or carboplatin, with optional bevacizumab. Those whose cancer does not worsen are randomized to receive either pembrolizumab alone or sac-TMT plus pembrolizumab, with optional bevacizumab for maintenance treatment. Treatments are given by intravenous infusion at specified doses and schedules over several months. Participants will be closely monitored throughout the study with regular visits to assess safety, cancer progression, and quality of life. Researchers will track adverse events, treatment tolerability, progression-free survival, and overall survival. Quality of life questionnaires and physical functioning assessments are included to understand the impact of treatment. The study duration may extend up to approximately 69 months for safety follow-up, with various outcome measures evaluated at set intervals.

Age: 18Years +FEMALEPhase 3
191 locations
R

Actively Recruiting

This research aims to collect real world evidence on adult patients in Argentina diagnosed with acute promyelocytic leukemia APL who receive first-line treatment using arsenic trioxide plus all trans retinoic acid ATOATRA based regimens. The study evaluates outcomes including event-free survival and overall survival, with additional focus on complete molecular response rates, treatment toxicity, early mortality, and the prognostic role of the FLT3 mutation. Patients will follow local guidelines where risk is determined by white blood cell counts high-risk WBC >10,000 or low-risk WBC <10,000. All patients receive induction with daily ATO plus ATRA until remission or for up to 60 days. High-risk patients also receive 2-3 doses of idarubicin at induction start. Consolidation includes cycles of ATO given 5 days a week in alternating 4-week periods and ATRA in alternating 2-week periods. Central nervous system prophylaxis is provided for high-risk patients or those with CNS bleeding. Participants will be monitored through molecular testing at consolidation end and periodically for high-risk patients during the first two years. Researchers will collect data on survival outcomes, molecular remission, toxicity, and early mortality. The study involves following patients over 36 months to assess long-term treatment effects and prognostic markers.

Age: 18Years +All Genders
6 locations